GSK's pullback from low-margin contract manufacturing drags on results

By Nick Taylor

- Last updated on GMT

(Image: Getty/Limpido)
(Image: Getty/Limpido)

Related tags Gsk Consumer Health

GSK blames retreat from low-margin contract manufacturing for flat fourth quarter performance of consumer health unit.

Previously, GlaxoSmithKline combined its consumer health division with that of Pfizer to create a joint venture​ (JV). GSK is now preparing the Pfizer consumer health joint venture to operate as a standalone operation independent of its branded prescription drug business.

Iain Mackay, CFO at GSK, provided an update on the joint venture on the company’s fourth quarter results conference call, noting the impact on sales of a shift in its contact manufacturing strategy.

Mackay said, “Revenues of the new consumer healthcare JV were up 2% on a pro forma basis, despite a drag of around 1% from the combined impact of divestments and the phasing out of low-margin contract manufacturing​.”

GSK’s phasing out of low-margin contract manufacturing hit the wellness division of its consumer health joint venture. The loss of contract manufacturing business offset growth of pain medicines, such as Panadol (paracetamol) and Advil (ibuprofen), resulting in flat sales at the wellness division on a pro forma basis.

The decision to phase out contract manufacturing work that generates revenues, albeit at a margin below that desired by GSK, has fed into an investor debate about the trade off between profitability and growth at consumer health companies.

GSK’s decision to pull back from low-margin contract manufacturing contributed to flat performance at the consumer health unit in the fourth quarter and restricted it to a 2% increase in sales for the full year. In effect, GSK sacrificed growth to get out of low-margin work.

James Gordon, an analyst at JPMorgan, used GSK’s conference call to sketch out why some investors are questioning whether consumer healthcare companies in general are striking the right balance between growth and margins.

Gordon said, “There has been some debate from some investors who ask whether consumer companies need to sacrifice some of the increase in the high profitability they have been achieving to invest more to actually get faster growth​.”

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more